FY25 Bulk Pharma Buy (Materiel)
ID: BulkPharmaC-MaterielType: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR/ORM-SNSAtlanta, GA, 30341, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/416c72e29fa04d7f8482d5758760f357/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from vendors regarding the procurement of pharmaceuticals for the Strategic National Stockpile (SNS) under the FY25 Bulk Pharma Buy initiative. The primary objective is to identify suppliers capable of providing FDA-approved medications, including Amoxicillin, Ciprofloxacin, and Clindamycin, in specified formulations and quantities, as detailed in the associated RFI documents. This procurement is crucial for ensuring rapid access to essential medical supplies during public health emergencies, such as biological or chemical threats and natural disasters. Interested vendors must submit their capabilities and relevant information electronically by January 9, 2025, to Terri Reed at terri.reed@hhs.gov, with the understanding that responses will not be returned and will be treated as public knowledge.

    Point(s) of Contact
    Terri Reed
    terri.reed@hhs.gov
    Files
    Title
    Posted
    RFI Attachment A (FY25 Materiel Program Pharma).xlsx
    This document outlines a request for proposals (RFP) related to the procurement of various pharmaceutical products, specifically oral suspensions and injectable solutions, for use by government agencies. Key products listed include Amoxicillin, Ciprofloxacin, and Clindamycin, along with their respective National Drug Code (NDC) numbers and packaging details. Potential vendors are requested to provide critical information, including company size, drug compliance with Trade Agreements, inventory management strategies for emergencies, delivery timelines, volume discounts, and any prior government contract awards relevant to these products. The document aims to ensure that bidders demonstrate capacity, compliance, and existing infrastructure capable of meeting the government's pharmaceutical needs over a specified contract period. Ultimately, this RFP serves to identify qualified suppliers who can consistently provide high-quality medications while adhering to regulatory standards and having contingency plans for maintaining supply in emergency situations.
    RFI for Vendors (FY25 Materiel Program Pharma).docx
    The U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response (ASPR) issued a Request for Information (RFI) concerning the Strategic National Stockpile (SNS). The SNS's primary mission is to provide rapid access to life-saving medical supplies and pharmaceuticals in response to public health emergencies, including biological, chemical, and radiological threats, as well as natural disasters. This RFI seeks information from vendors capable of supplying FDA-approved pharmaceuticals pertinent to the SNS's mission. The document serves as a market research tool and does not obligate the government to issue a contract or accept unsolicited proposals. Interested vendors, both large and small, are encouraged to submit their capabilities and relevant business information while considering potential compliance with small business regulations. A submission deadline of January 9, 2025, is outlined, and all responses must be sent electronically. The document emphasizes that provided information will not be returned and will be treated as public knowledge. This RFI reflects the government's commitment to securing diverse vendor participation in developing its pharmaceutical stockpile.
    Lifecycle
    Title
    Type
    FY25 Bulk Pharma Buy (Materiel)
    Currently viewing
    Sources Sought
    Similar Opportunities
    Public Health Industrial Base Capabilities and Capacities: Anti-Microbials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking industry partners to provide information regarding domestic production capabilities related to anti-microbials under the Defense Production Act Title III Program. The objective of this Request for Information (RFI) is to identify gaps in the Public Health Industrial Base (PHIB) and enhance national defense resources by focusing on the production of essential medicines and medical countermeasures sourced domestically. Respondents are encouraged to share insights on their manufacturing processes, regulatory compliance, and infrastructure, as well as past supply chain disruptions and investment needs, with responses due by January 6, 2025, at 10 AM ET. Interested parties should submit their responses to Chris Newell at IBMSC-Submissions@hhs.gov.
    Doxycycline Hyclate Solicitation
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. This procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with specific requirements outlined for compliance with federal regulations, including business ethics and subcontracting plans. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for maintaining adequate supplies for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Courtney Hunter-Stangler or Jason C. Wray for further information regarding the solicitation.
    Emergency Deployment and Mobilization Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), is seeking information on potential providers for Emergency Deployment and Mobilization Services. The objective is to identify sources capable of quickly deploying HHS responders during crises such as pandemics, natural disasters, and special security events, with a focus on efficient transportation, lodging, and logistical support. This Request for Information (RFI) aims to gather insights on industry capabilities to manage bulk travel requests and provide real-time communication support, informing future contract proposals without obligating the government to procure services. Interested vendors must submit a white paper detailing their capabilities by January 7, 2024, and can contact Shayla Kelley at shayla.kelley@hhs.gov for further inquiries.
    Request for Information - Enhancing Pharmacy Countermeasures in Independent Pharmacies
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking insights through a Request for Information (RFI) aimed at enhancing pharmacy countermeasures in independent pharmacies. The objective is to gather information from pharmacy partners, vendors, and associations regarding the necessary capabilities and infrastructure for independent pharmacies to effectively deliver health services, including testing, vaccines, and therapeutics, particularly to under-resourced populations. This initiative is crucial as independent pharmacies play a vital role in public health, especially in rural areas, and the information collected will inform strategies to improve service delivery and public health response capacity. Interested parties can contact Dawn Redman at dredman@cdc.gov or call 404-498-3069 for further details.
    6505--765_Pharmaceuticals_VA CMOP Hines_36C77025Q0088 765-25-1-021-0194 -Hines CMOP 4 PHARMACEUTICALS -(VA-25-00028394)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified vendors to supply various pharmaceuticals for delivery to the Consolidated Mail Outpatient Pharmacy (CMOP) in Hines, Illinois, under solicitation number 36C77025Q0088. The procurement includes specific items such as PEG-400 solution, Sevelamer carbonate tablets, Fenofibrate capsules, and Febuxostat tablets, with a total quantity specified for each item. These pharmaceuticals are essential for ensuring the health and well-being of veterans, highlighting the importance of a reliable supply chain in the healthcare sector. Interested vendors must submit their quotes, including a signed SF 1449 cover page and compliance documentation, by December 27, 2024, at 9:00 AM CST, with the estimated award date set for December 31, 2024. For further inquiries, vendors can contact Jeffrey A. Blackard at jeffrey.blackard@va.gov or by phone at (913) 684-0142.
    6505--770_Pharmaceuticals_VA CMOP National Office_36C77025Q0099 770-25-1-801-0137 -National CMOP FENOFIBRATE
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified vendors to fulfill an emergency procurement of Fenofibrate Pharmaceuticals for the Consolidated Mail Outpatient Pharmacy (CMOP), under solicitation number 36C77025Q0099. The procurement requires multiple quantities of Fenofibrate 145MG 90CT, with specific delivery to various CMOP facilities across the United States, emphasizing compliance with the Buy American statute. This initiative is crucial for ensuring the availability of essential pharmaceuticals for veterans, reflecting the VA's commitment to providing timely medical supplies. Interested vendors must submit their proposals by December 30, 2024, at 09:00 AM CST, including a signed SF1449 cover page, a detailed price schedule in Excel format, proof of state wholesale distributor licensure, and a completed Buy American certificate, with all submissions directed to Contract Specialist Michael W. McAlhaney at Michael.McAlhaney@va.gov.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    6505--Cyclobenzaprine Tablets (VA-25-00015093)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Cyclobenzaprine HCL Tablets under solicitation number 36E79725R0009. This unrestricted procurement aims to secure a reliable supply of these essential pharmaceuticals for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), reflecting the government's commitment to providing necessary medications to veterans and associated healthcare systems. The contract will have an initial duration of one year, with the possibility of four additional one-year extensions, and interested vendors must provide specific drug labeling along with a unique National Drug Code (NDC). The RFP is expected to be released electronically around December 20, 2024, with a submission deadline set for January 3, 2025. For further inquiries, interested parties can contact Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotes for a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) related to the procurement of pharmaceutical agents as part of its Uniform Formulary (UF) initiative. This procurement aims to establish an effective and integrated pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of newly approved drugs, including neurological agents, antibiotics, oncological agents, and various other pharmaceutical categories. Interested manufacturers must submit their quotes by January 16, 2025, with a pre-quotation teleconference scheduled for January 8, 2025, to discuss the requirements and expectations. For further inquiries, manufacturers can contact Tracy Banks at tracy.e.banks2.civ@health.mil or Patricia Tyson at patricia.a.tyson3.ctr@health.mil.